GFAP/NF-κB/APOE/NLRP3-IN-1 

GFAP/NF-κB/APOE/NLRP3-IN-1 is an orally active, blood-brain barrier-permeable multi-target inhibitor with an IC₅₀ of 3.50 nM against Acetylcholinesterase. GFAP/NF-κB/APOE/NLRP3-IN-1 inhibits BACE-1 with an IC₅₀ of 14.61 nM. GFAP/NF-κB/APOE/NLRP3-IN-1 inhibits Aβ_1-42 aggregation with an IC₅₀ of 8.63 μM. GFAP/NF-κB/APOE/NLRP3-IN-1 reduces the levels of GFAP, NLRP3 inflammasome, NF-κB and APOE. GFAP/NF-κB/APOE/NLRP3-IN-1 is applicable for the research of Alzheimer's disease and neuroblastoma^[1].

GFAP/NF-κB/APOE/NLRP3-IN-1 (Compound 11a) potently inhibits human acetylcholinesterase with an IC₅₀ of 3.50 nM, acting as a hybrid inhibitor targeting both the catalytic and peripheral anionic sites of the enzyme^[1].
GFAP/NF-κB/APOE/NLRP3-IN-1 inhibits butyrylcholinesterase with an IC₅₀ of 4.30 μM, showing greater potency than donepezil^[1].
GFAP/NF-κB/APOE/NLRP3-IN-1 inhibits BACE-1 with an IC₅₀ of 14.61 nM, demonstrating greater potency and higher selectivity over BACE-2 than the reference drug ly2886721^[1].
GFAP/NF-κB/APOE/NLRP3-IN-1 inhibits Aβ_1-42 aggregation with an IC₅₀ of 8.63 μM, showing significantly greater potency than donepezil^[1].
GFAP/NF-κB/APOE/NLRP3-IN-1 has a comparable safety profile to donepezil in SH-SY5Y neuroblastoma cells, with an IC₅₀ of 80.3 μg/mL, and does not cause significant cytotoxicity at concentrations used for Aβ aggregation inhibition^[1].
GFAP/NF-κB/APOE/NLRP3-IN-1 exhibits high blood-brain barrier permeability with an effective permeability coefficient of 21.08 × 10^-6 cm/s, classifying it as CNS-permeable and showing greater permeability than donepezil^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Compound 11a (20 mg/kg; p.o.; daily; 7 days) significantly improves cognitive function, reduces cholinergic dysfunction, amyloid-β accumulation, neuroinflammatory mediators, and oxidative stress, and mitigates neuronal damage in LPS-induced Alzheimer's disease mice^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

573.60

C₃₂H₂₇N₇O₄

CC1=CC(OC2=C1C=CC(OCC(N/N=C/C3=CN(N=C3C4=C(N(N=N4)C5=CC=CC=C5)C)C6=CC=CC=C6)=O)=C2C)=O

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. El-Mokaddem OK, et al. Multi-target Triazole-Benzopyrone hybrids modulating cholinergic dysfunction, oxidative stress, and neuroinflammation through GFAP/NF-κB/APOE/NLRP3 axis in Alzheimer's disease. Eur J Med Chem. 2026 May 13;315:118949.  [Content Brief]